tag:blogger.com,1999:blog-48369030770608098222024-02-02T12:33:28.662-08:00Middle East Heart Congress<b>Theme:</b> Extending our Reach to make Heart Healthy<br>
<b>Date:</b> March 18-20, 2019 <br>
<b>Conference Venue:</b> Dubai, UAE
Asia Pacific Conferencehttp://www.blogger.com/profile/10138955357050690328noreply@blogger.comBlogger10125tag:blogger.com,1999:blog-4836903077060809822.post-21876454732171644502018-10-11T21:56:00.001-07:002018-10-11T21:56:12.205-07:00Study reveals that Cardiomyopathy mutation reduces heart's ability to vary pumping force.<div dir="ltr" style="text-align: left;" trbidi="on">
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-IN</w:LidThemeOther>
<w:LidThemeAsian>X-NONE</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-fareast-language:EN-US;}
</style>
<![endif]-->
<br />
<div class="MsoNormal" style="background: white; line-height: 17.25pt; margin-bottom: 11.25pt; margin-left: 0cm; margin-right: 0cm; margin-top: 3.75pt; text-align: justify;">
<span style="color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;">Recently, the Researchers have found how a genetic mutation is associated to </span><a href="https://heart.cardiologymeeting.com/events-list/cardiovascular-disease-and-nutrition"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;">hypertrophic cardiomyopathy</span></a><span style="color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;"> (HCM) disrupts the heart's normal function. The study reveals that the mutation prevents the heart from increasing the amount of force it produces when it needs to pump additional blood around the body.</span><span style="color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;"><span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> </span></span></div>
<div class="MsoNormal" style="background: white; line-height: 17.25pt; margin-bottom: 11.25pt; margin-left: 0cm; margin-right: 0cm; margin-top: 3.75pt; text-align: justify;">
<span style="color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;"><span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Inherited genetic mutations can cause in the heart muscle which can abnormally thick and reduce the pumping of enough blood around the body. Studies have identified a mutation in the heart muscle protein troponin T that seem to pose a particularly high risk of sudden death in children and adults, despite it having only a mild thickening of the heart muscle wall. The mutation, known as F87L, alters a single amino acid in the central region of troponin.</span></span><span style="color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;"></span></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> </span></div>
<span style="color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;"><div class="separator" style="clear: both; text-align: center;">
<span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"></span>
</div>
</span><br />
<div class="MsoNormal" style="text-align: justify;">
<a href="https://heart.cardiologymeeting.com/"><span style="background: white; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Troponin</span></a><span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> complex component Troponin T which allows muscle fibers to contract in response to calcium released upon electrical stimulation. One of the significant features of cardiac muscle filaments is: they become more sensitive to calcium and hence contract more strongly, because they are stretched to longer lengths. Hence, when <a href="https://heart.cardiologymeeting.com/abstract-submission.php">heart</a> is filled with more blood, especially during carrying out <a href="https://heart.cardiologymeeting.com/events-list/clinical-cardiology">physical activity</a>, the muscle walls stretches and the heart contracts with high force to pump out extra blood. This phenomenon, which is known as the Frank-Starling mechanism is mainly due to Troponin action.</span><span style="color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN;"></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiBTkYA_5o0JO-M0JiInYfOTMe7_hRhClCsP1JmGgNYrEZFT-pVqjlqvHG9Fk97Xx8NBQhfUb4ctTjGGkAgnu3NIPgRu6kdPCoOJ1U-pJl66RygrfonLG1Zi6l9j7qGYBGykcSSNlctrJxd/s1600/sds.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="256" data-original-width="512" height="200" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiBTkYA_5o0JO-M0JiInYfOTMe7_hRhClCsP1JmGgNYrEZFT-pVqjlqvHG9Fk97Xx8NBQhfUb4ctTjGGkAgnu3NIPgRu6kdPCoOJ1U-pJl66RygrfonLG1Zi6l9j7qGYBGykcSSNlctrJxd/s400/sds.png" width="400" /></a></div>
<br />
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> </span><span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">A professor along with a graduate student carried out research and introduced an equivalent mutation in the cardiac troponin T gene of guinea pigs and analyzed how it can affects the guinea pigs <b style="mso-bidi-font-weight: normal;"><i style="mso-bidi-font-style: normal;">cardiac muscle</i></b> fibers ability to contract and produce force. They found that the mutation: F87L in troponin T destroys the length-dependent increase in calcium sensitivity. the same response to calcium was observed in short, unstretched muscle fibers expressing mutant troponin T showed just as longer, stretched fibers.</span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">The data resulted demonstrate that the length-mediated increase in force is significantly decreased by this <b style="mso-bidi-font-weight: normal;"><i style="mso-bidi-font-style: normal;">hypertrophic cardiomyopathy (HCM)-</i></b>associated mutation, which suggested that the mutation may direct muscle length-mediated increase in force production in the heart.. The </span><span style="background: white; color: #222222; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">effect</span><span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> of the Frank-Starling mechanism may have severe consequences for any individual as it decreases the heart's ability to increase output when it needs to pump additional blood around the body.</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">For more visit:</span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> </span><a href="https://heart.cardiologymeeting.com/"><span style="background: white; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">https://heart.cardiologymeeting.com/</span></a></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Submit your abstract : <a href="https://heart.cardiologymeeting.com/abstract-submission.php">https://heart.cardiologymeeting.com/abstract-submission.php</a></span><span style="background: white; color: #333333; font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"></span></div>
</div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-90773908050481735882018-10-08T00:16:00.002-07:002018-10-08T00:16:47.129-07:00Association between Breastfeeding in reducing Hypertension risk<div dir="ltr" style="text-align: left;" trbidi="on">
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-IN</w:LidThemeOther>
<w:LidThemeAsian>X-NONE</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-fareast-language:EN-US;}
</style>
<![endif]-->
<br />
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif";"><a href="https://heart.cardiologymeeting.com/events-list/women-and-heart-disease">Women</a> who breastfeed more children, and intended for the long period, are less likely to suffer from hypertension once they reach menopause. This is not true of obese women, however. Elevated <i style="mso-bidi-font-style: normal;">blood pressure </i>is the most prominent risk factor for disease and death. Proof from <i>epidemiologic</i> data has too revealed the advantageous effects of breastfeeding on the <b>healthiness </b></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhZFE0DYuJlrELn8yI5CcvRHYmcQNPY53fGf61Sx2uWpWp1gsuGyznOZ3fEcjrvQHqogTFBBrczfZztyhNGPGjXNhdaAXfLlNN1-h8Zi0DRtbcicl4uRPAHnJWHKafAvukBtBpB4o6T1Dq7/s1600/BreastfeedingHeart+2019.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="720" data-original-width="1280" height="225" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhZFE0DYuJlrELn8yI5CcvRHYmcQNPY53fGf61Sx2uWpWp1gsuGyznOZ3fEcjrvQHqogTFBBrczfZztyhNGPGjXNhdaAXfLlNN1-h8Zi0DRtbcicl4uRPAHnJWHKafAvukBtBpB4o6T1Dq7/s400/BreastfeedingHeart+2019.jpg" width="400" /></a></div>
of infants and their mothers. It has been reported that long-term breastfeeding is linked with reduced children's allergies, celiac disease, obesity, and <b style="mso-bidi-font-weight: normal;">diabetes mellitus</b>. Though, the effects of breastfeeding on maternal health have been not much studied compared with the effects on the children.<br />
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif";">Numerous studies reliably found that lacking breastfeeding or early discontinuation was related with increased risks of <i style="mso-bidi-font-style: normal;">diabetes mellitus</i>, </span><a href="https://heart.cardiologymeeting.com/events-list/heart-disease-and-failure"><span style="font-family: "Times New Roman","serif";">dyslipidemia</span></a><span style="font-family: "Times New Roman","serif";">, <i style="mso-bidi-font-style: normal;">metabolic disorder</i>, <i style="mso-bidi-font-style: normal;">coronary heart disease</i>, and <b style="mso-bidi-font-weight: normal;">cardiovascular diseases</b>. </span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif";">On the other hand few studies have recognized a clear relationship </span><span style="font-family: "Times New Roman","serif";"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh_Lmr-Bg3Kwk28kTIQkCXx5sG624gSwxalIJrWzfMyKy5hMApL4aK2Gq01sr0DntXjBUnIITcJ2qs-y8hxbEn7LDq3FjqHiAc0MM5r4snW07STWuza5Mwh9ERlcxza_CmyRvhlEKsmx0tl/s1600/Association+between+Breastfeeding+in+reducing+Hypertension+risk.jpg" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="789" data-original-width="940" height="167" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh_Lmr-Bg3Kwk28kTIQkCXx5sG624gSwxalIJrWzfMyKy5hMApL4aK2Gq01sr0DntXjBUnIITcJ2qs-y8hxbEn7LDq3FjqHiAc0MM5r4snW07STWuza5Mwh9ERlcxza_CmyRvhlEKsmx0tl/s200/Association+between+Breastfeeding+in+reducing+Hypertension+risk.jpg" width="200" /></a>between breastfeeding and hypertension. The study population comprised 3,119 non-smoking postmenopausal women aged 50 years or older was taken under consideration. More children breastfed and the longer period of </span><a href="https://heart.cardiologymeeting.com/events-list/women-and-heart-disease"><span style="font-family: "Times New Roman","serif";">breastfeeding</span></a><span style="font-family: "Times New Roman","serif";"> was associated with minor risk of <i style="mso-bidi-font-style: normal;">hypertension</i> in postmenopausal women, and level of obesity and <i style="mso-bidi-font-style: normal;">insulin</i> resistance directed the breastfeeding-hypertension correlation. In particular, the highest quintile of number of children breastfed (5 to 11) appeared a 51% lessen risk of </span><a href="https://heart.cardiologymeeting.com/events-list/cardiac-and-cardiovascular-research"><span style="font-family: "Times New Roman","serif";">hypertension</span></a><span style="font-family: "Times New Roman","serif";"> compared by the lowest quintile (0 to 1). The highest quintile of the duration of breastfeeding (96 to 324 months) showed a 45% lower risk of hypertension. </span></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif";"></span><span style="font-family: "Times New Roman","serif";">Even though a broad variety of chronic diseases are not linked with breastfeeding, a few common mechanisms have been anticipated to lie behind the relationships between <b style="mso-bidi-font-weight: normal;">breastfeeding</b> and these diseases. First, maternal metabolism (e.g., fat accumulation and insulin resistance) may be "reorganize" by breastfeeding subsequent to <i style="mso-bidi-font-style: normal;">pregnancy</i>, which diminishes the risk of obesity-related diseases. Second, <b style="mso-bidi-font-weight: normal;">oxytocin </b>discharge stimulated by breastfeeding may be related to the decreased risk of these diseases.</span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif";"></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-IN; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;">Website: </span><span style="font-family: "Calibri","sans-serif"; font-size: 11.0pt; line-height: 115%; mso-ansi-language: EN-IN; mso-ascii-theme-font: minor-latin; mso-bidi-font-family: "Times New Roman"; mso-bidi-language: AR-SA; mso-bidi-theme-font: minor-bidi; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin;"><a href="https://heart.cardiologymeeting.com/"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">https://heart.cardiologymeeting.com/</span></a></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-IN; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;"><span style="mso-spacerun: yes;"> </span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-IN; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;"><span style="mso-spacerun: yes;">any query: heart@memeetings.com </span></span>
</div>
</div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-67153519064139401382018-09-21T00:03:00.000-07:002018-09-21T00:03:03.286-07:00Predictors associated with augmented Left ventricular systolic function after pulmonary valve replacement<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="background: white; margin-bottom: 11.25pt; margin-left: 0cm; margin-right: 0cm; margin-top: 3.75pt; text-align: justify;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEimVRbnhLe3ucGAlk_NxySyvOQPjiGNx7S1uDF1QLaBqFQGs1K5iThGzWCZR7hT8NRLofcqJJFAxzmhGJU13WhmKS9jhCfwtkrLT6ILETHNiIbbsL41PTYDBR62WaECVDEA4ldNb2VdMofp/s1600/images.jpg" imageanchor="1" style="background-color: transparent; clear: left; float: left; margin-bottom: 1em; margin-right: 1em; text-align: center;"><img border="0" data-original-height="183" data-original-width="275" height="132" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEimVRbnhLe3ucGAlk_NxySyvOQPjiGNx7S1uDF1QLaBqFQGs1K5iThGzWCZR7hT8NRLofcqJJFAxzmhGJU13WhmKS9jhCfwtkrLT6ILETHNiIbbsL41PTYDBR62WaECVDEA4ldNb2VdMofp/s200/images.jpg" width="200" /></a><span style="color: #333333;"><a href="https://heart.cardiologymeeting.com/events-list/pediatric-cardiology">Tetralogy of Fallot</a> (TOF) has been more than five decades since the first total TOF repair was performed in 1955. TOF accounts for almost 10% of all cases of congenital heart disease and is one of the main common cyanotic congenital heart disorder. Reparative surgery grants more than 85% of children born with TOF to continue into adulthood. Through the development of surgical procedures, perioperative encourage, and imaging modalities, long-term results have also considerably progressed in the previous 2 decades, but resultant anomalies such as significant right ventricular (RV) enlargement, dyskinetic severe pulmonary regurgitation (PR), interventricular septal motion, and reduced RV systolic functioning are still there in more than half of these patients. It is now commonly acknowledged that <a href="https://heart.cardiologymeeting.com/">pulmonary valve replacement</a> (PVR) in patients with severe PR and concomitant RV volume overload can consequence in the preservation or recovery of RV function.</span></div>
<div style="text-align: justify;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9R3Mfhlb0AvzuXPn5eQkpOppPFb0UHiXVVbbePOUBQllaDiyBziW7tyr1ISMoAPCRTh86fEjoSx8WyhnqFSXZp8IKF9f14fjFT1vIl7_TDMy0HpsV3RBQCa-s212wHz8nxAM474N9qN5j/s1600/Untitled+design+%25287%2529.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em; text-align: center;"><img border="0" data-original-height="315" data-original-width="560" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9R3Mfhlb0AvzuXPn5eQkpOppPFb0UHiXVVbbePOUBQllaDiyBziW7tyr1ISMoAPCRTh86fEjoSx8WyhnqFSXZp8IKF9f14fjFT1vIl7_TDMy0HpsV3RBQCa-s212wHz8nxAM474N9qN5j/s320/Untitled+design+%25287%2529.jpg" width="320" /></a><span style="background-color: white; color: #333333; text-align: justify;">As such, much of the present literature on <i>congenital heart disorder</i> centers on </span>the preservation<span style="background-color: white; color: #333333; text-align: justify;"> and recovery of RV function in patients with repaired <b>TOF</b> (</span>rTOF<span style="background-color: white; color: #333333; text-align: justify;">).</span><span style="background-color: white; color: #333333;"> Although LV volume and systolic function can </span>fluctuate<span style="background-color: white; color: #333333;"> in adults at the late stage after TOF repair, PVR may have other benefits on LV systolic function. Researchers found that the only independent CMR indicator of postoperative improvement in LV systolic function is preoperative LV systolic dysfunction. This may be auxiliary to normalization of interventricular interactions after PVR, but the exact mechanisms responsible are not known yet. Other study </span>is<span style="background-color: white; color: #333333;"> needed to further analyze the findings and determines accurate predictors associated with augmented LVEF following PVR.</span></div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333;"><br /></span></div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333;">Visit: </span><span style="text-align: left;"><span style="color: #333333;"><a href="https://heart.cardiologymeeting.com/">https://heart.cardiologymeeting.com/</a></span></span></div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333; text-align: justify;"><br /></span></div>
<div style="text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgKismalYT4OP21v93aTsvuJnUd1ysnPfawqYb9L877_x1OBMeGx83hRff3fYFWCbwqyQxrM7EMZghqwrV7gO2HgfZCJ6ZdYii4JyOZMwjTEabE74T4AU1XR3b5mZ6NhgPKBCreDXXyk2OK/s1600/Untitled+design+%25287%2529.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em; text-align: center;"><img border="0" data-original-height="315" data-original-width="560" height="225" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgKismalYT4OP21v93aTsvuJnUd1ysnPfawqYb9L877_x1OBMeGx83hRff3fYFWCbwqyQxrM7EMZghqwrV7gO2HgfZCJ6ZdYii4JyOZMwjTEabE74T4AU1XR3b5mZ6NhgPKBCreDXXyk2OK/s400/Untitled+design+%25287%2529.jpg" width="400" /></a></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333; text-align: justify;"><br /></span></div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333; text-align: justify;"><br /></span></div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333; text-align: justify;"><br /></span></div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333; text-align: justify;"><br /></span></div>
</div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-52876134355993205292018-09-07T22:57:00.000-07:002018-09-07T22:57:45.216-07:00How Sugar is more likely to cause high blood pressure and heart disease..??<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Nutritional guidelines should highlight the role played by supplementary sugars, predominantly fructose, in the combat to control the prevalence of cardiovascular diseases. Cardiovascular disease is the main cause of premature death in the developed world. In addition to high blood pressure is its most important risk factor, accounting for almost 350,000 deaths in the US in 2009 and costing more than $50 billion US dollars every year. Dietary approaches to reduce high blood pressure have historically focused on cutting salt intake. But the possible benefits of this methodology "are debatable. This is for the reason that the average reductions in blood pressure accomplished by confining salt intake tend to be relatively little, and close by is some evidence to suggest that 3-6 g salt daily might be optimal for health, and to ingestion below 3 g may, in fact, be more dangerous. Most salt in the diet comes from processed foods, which also happen to be a loaded source of supplementary sugars.<o:p></o:p></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgPE8Ric19b7qJzRQOMJnrV5LWTXoHwcgwJInGjoWxRhLsjqfCt6GmZ0nCGJAlq52MRmIFEMyJPLm8ZV_mi9Lbc84tEjUOTL6yK9aaOGy67YBCnRzsFVtBS5t069TjNefM6bkSo_bgGwjLS/s1600/8-9-2018.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="315" data-original-width="600" height="168" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgPE8Ric19b7qJzRQOMJnrV5LWTXoHwcgwJInGjoWxRhLsjqfCt6GmZ0nCGJAlq52MRmIFEMyJPLm8ZV_mi9Lbc84tEjUOTL6yK9aaOGy67YBCnRzsFVtBS5t069TjNefM6bkSo_bgGwjLS/s320/8-9-2018.png" width="320" /></a></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">"Sugar can be much more evocatively associated to blood pressure than sodium, as proposed by a greater amount of effect with dietary maneuvering. “Compelling evidence from basic science, population studies, and clinical trials ensnare sugars, and particularly the monosaccharide fructose, as playing a chief role in the growth of hypertension [high blood pressure]. "Moreover, evidence recommends that sugars in common, and fructose, in particular, may be a factor to generally cardiovascular hazard through a variety of components. High fructose corn syrup, which is the most frequently utilized as a sweetener in processed foods, especially in fruit-flavored and fizzy drinks. "Worldwide, sugar-sweetened drink consumption has been implicated in 180,000 deaths a year". Around 300 years ago, individuals only devoured a few pounds of sugar a year, while current estimates advise that average intake in the US is 77-152 pounds a year--equivalent to 24-47 teaspoons a day.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">The evidence proposes that people whose food intake of supplementary sugars adds up to at least a quarter of their aggregate daily calories have nearly triple the cardiovascular disease risk of individuals who consume less than 10%. And a daily ingestion of more than 74 g of fructose is linked with a 30% more prominent risk of blood pressure more than 140/90 mm Hg and a 77% amplified risk of blood pressure above 160/100 mm Hg. A high fructose diet has as well been linked to a troublesome blood fat profile, elevated fasting blood insulin levels, and a doubling-up the risk of metabolic syndrome. Some dietary guidelines do incorporate suggestions about daily intake of supplementary sugars, but are not stern enough, nor do they make definite recommendations concerning fructose.<o:p></o:p></span></div>
<br />
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"> Naturally-occurring sugars found in fruit and vegetables are not harmful to health. Eating fruit and vegetables is almost certainly beneficial.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">for more visit: <a href="https://heart.cardiologymeeting.com/">https://heart.cardiologymeeting.com</a></span></div>
</div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-37024773218812094132018-08-18T02:06:00.001-07:002018-08-18T02:06:32.538-07:00Steroid Hormone Imbalance Leading to Treatment-Resistant Hypertension<div dir="ltr" style="text-align: left;" trbidi="on">
<br />
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Studies carried by
Researchers of London, found that the <b style="mso-bidi-font-weight: normal;">steroid
hormone</b> 'aldosterone' makes salt amass in the circulation system. The salt
aggregation happens even in patients on sensible eating methodologies, and
pushes up pulse regardless of utilization of diuretics and other standard
medications. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Two patients in the
examination with already resistant hypertension could fall off all medications
after a benign aldosterone-causing nodule formation in one adrenal and
surgically removed after medical procedure. <o:p></o:p></span></div>
<div class="separator" style="clear: both; text-align: center;">
<img border="0" data-original-height="315" data-original-width="560" height="225" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjRfcmNTPLNKqgdYwOEd8H94pVbcV5dyDRYFty7BtbbI0zH8TizMimLDQ4VwazRUZxNZW9XhjCv1JWDMlHrk-twWh1EzPgx0wDlPRuV3nwsS368C4okA5e6KLUCszUn6JTJjDGfglYru8ty/s400/Heart2019.png" width="400" /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<a href="https://heart.cardiologymeeting.com/events-list/heart-disease-and-failure"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Hypertension</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">
standouts amongst the most widely recognized and imperative preventable reasons
for heart diseases, heart disappointment, stroke and sudden passing. It influences
more than 1 billion individuals over the world and records for around 10
million possibly avoidable death for every year. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">Most patients can be
dealt with successfully with changes in accordance with their way of life and
the utilization of consistent prescription. In any case, in upwards of 1 of
every 10 patients, circulatory strain can be hard to control and is named <i style="mso-bidi-font-style: normal;">'resistant hypertension'</i>. These patients
are at the most astounding danger of stroke and coronary illness in light of
the fact that their circulatory strain stays uncontrolled. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">There has been an
awesome story of utilizing refined current techniques to tackle an old issue -
why a few patients have clearly recalcitrant hypertension. The revelation of
salt over-burden as the basic reason has empowered us to distinguish the
hormone which drives this, and to treat or fix the greater part of the
patients.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">These outcomes are
vital on the grounds that they will change clinical practice over the world and
will help enhance the circulatory strain and results of our patients with </span><a href="https://heart.cardiologymeeting.com/"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">resistant hypertension</span></a><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">.
<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">It is noteworthy when
such a large number of advances in prescription rely upon costly advancement,
that we have possessed the capacity to return to the utilization of medications
created over 50 years prior and demonstrate that for this hard to-treat
populace of patients, they work extremely well.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">In past work, the group
demonstrated that resistant hypertension is controlled much better by the medication
spironolactone (a steroid blocker of aldosterone) than by drugs authorized for
use in hypertension. Presently they have demonstrated that the prevalence of
spironolactone is expected over its capacity to beat the salt overabundance in
resistant hypertension. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">They likewise found
that spironolactone can be substituted, to great impact, by a medication,
amiloride, which could be a possibility for patients unfit to endure
spironolactone. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%;">The examination
originates from the PATHWAY-2 contemplate, some portion of a progression of
concentrates intended to grow more powerful methods for treating hypertension. It
explored the theory that resistant hypertension was fundamentally caused by an
imperfection in taking out salt and water and that the hypertension in these
patients would be best treated by extra diuretic treatment to advance salt and
water discharge by the kidneys.<o:p></o:p></span></div>
<a href="https://heart.cardiologymeeting.com/"><br /></a><br />
For more details: <span style="font-family: "Times New Roman", serif; font-size: 12pt; text-align: justify;">https://heart.cardiologymeeting.com/</span></div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-25318432885207948232018-08-10T00:54:00.000-07:002018-08-10T00:54:03.561-07:00Sudden Cardiac Death Peaks in Athlethes !!<div dir="ltr" style="text-align: left;" trbidi="on">
<br />
<div class="MsoNormal">
Sudden heart death (SCD) amid practice remains an uncommon,
yet destroying event in both youthful and more seasoned competitors. In more
youthful people, acquired heart conditions which incline the competitor to
deadly arrhythmias are the overwhelming reason, with the exact breakdown of
causes shifting by geographic area. This variety likely reflects worldwide
inconstancy in hereditary make-up. Arrhythmogenic right ventricular
cardiomyopathy (ARVC) is the most widely recognized reason for SCD in the
Veneto locale of Italy, and people with ARVC have a five-overlay increment in
the danger of SCD with practice than the individuals who don't practice. Since
SCD may the principal appearance of the hidden ailment in a generally
asymptomatic competitor, Italy has embraced routine screening of every single
Italian member in sorted out game to distinguish this, and other acquired
sicknesses prone to prompt SCD, with the goal that those influenced can get
treatment and be given proper exhortation in regards to sports cooperation,
most normally prohibition from aggressive game. Exact conclusion along these
lines requires dependable separation of those with hidden illness from those
competitors with the progressions of "competitor's heart". Likewise
with the left heart, there is noteworthy cover in discoveries of ARVC and those
of a competitor's heart prompting a huge clinical test. Impact of Exercise on
RV Structure and Function.<o:p></o:p></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiSLoIuhoh6CqRWdAYhvKiEnAK57jzj_SdPNtLfatwJO0sF6zlw5oVcnTUT9hOvtIyGEVgELT-SrD8fXxYubX2cMmbFosgiM3P3XraSKt5sLZMZZ2hcFv3vEYvi7ro6wvCQbNtStBKdtZiH/s1600/wwew.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="315" data-original-width="600" height="210" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiSLoIuhoh6CqRWdAYhvKiEnAK57jzj_SdPNtLfatwJO0sF6zlw5oVcnTUT9hOvtIyGEVgELT-SrD8fXxYubX2cMmbFosgiM3P3XraSKt5sLZMZZ2hcFv3vEYvi7ro6wvCQbNtStBKdtZiH/s400/wwew.png" width="400" /></a></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Similarly as has been portrayed in the left heart, standard
exercise preparing changes the structure and capacity of the correct side of
the heart. The discontinuous volume and weight heap of activity brings about
expanded right ventricular mass and depression size, and some expansion in
divider thickness. The expansion in right ventricular volume influences all
parts of the ventricle including the inflow, body and outpouring divides,
albeit a few information recommend that the privilege ventricular surge tract
(RVOT) redesigns not as much as different areas. Since the volume stack on the
left and right heart are the same amid work out, the level of left and right
ventricular widening is frequently comparable delivering an adjusted appearance
amongst left and right sides. In perseverance competitors, especially those
with high preparing volumes, the expansion of the RV can be very stamped and
may deliver more noteworthy change in the RV than the left ventricle (LV),
perhaps because of the more prominent increment in divider worry of the RV with
practice when contrasted with the LV. Accordingly a perseverance competitor
with manifestations which could be predictable with ARVC may have highlights of
right ventricular expansion on imaging thinks about and a suggestive ECG, in
this manner raising the likelihood of this imperative finding. It is likewise
important that the level of ECG change reflecting RV rebuilding, for example,
in deficient or finish right package branch square (RBBB) seems to mirror the
degree of RV renovating to such an extent that those competitors with an entire
RBBB have bigger RV volumes than those with inadequate RBBB (IRBBB) and the
littlest RV volumes are found in those with no type of RBBB. The test is to
isolate those with illness from those with a competitor's heart, especially in
the zones where discoveries cover.<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
For more: <a href="https://heart.cardiologymeeting.com/">https://heart.cardiologymeeting.com</a></div>
<br /></div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-34020936415066396432018-07-13T01:51:00.000-07:002018-07-19T09:54:42.924-07:00Association between vitamin D Deficiency and risk factors in women aged 50 Or Plus<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background: white; line-height: 17.25pt; margin: 3.75pt 0in 11.25pt; text-align: justify;">
<span style="font-family: "times" , "times new roman" , serif;">Results of studies carried out <span style="color: #333333; font-size: 10.5pt;">showed a strong relationship between vitamin D deficiency and <a href="https://heart.cardiologymeeting.com/events-list/women-and-heart-disease">metabolic syndrome </a>in postmenopausal women. The Metabolic syndrome (MetS), a condition when there is heightened risk of <a href="https://heart.cardiologymeeting.com/events-list/heart-disease-diagnosis-and-testing">heart disease</a>, stroke, and diabetes and it is estimated to affect approximately 50% of the female population above the age of 50 developed countries.</span><span style="color: #333333; font-size: 10.5pt;"><o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "times" , "times new roman" , serif;"><span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;">Around 57.8% of the women having MetS were analyzed with vitamin D insufficiency (20-29 nanograms per milliliter of blood) or deficiency (less than 20 ng/ml) and about 39.8% of them with sufficient vitamin D (30 ng/ml or more).</span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;"><span style="font-family: "times" , "times new roman" , serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: left;">
</div>
<div style="text-align: justify;">
<span style="background-color: white; color: #333333; font-family: "times" , "times new roman" , serif; font-size: 10.5pt;">To prove the indication whether or not the patient has MetS, typical parameters for </span>MetS<span style="background-color: white; color: #333333; font-family: "times" , "times new roman" , serif; font-size: 10.5pt;"> </span><a href="https://heart.cardiologymeeting.com/events-list/heart-disease-diagnosis-and-testing" style="font-family: Times, "Times New Roman", serif; font-size: 10.5pt;">diagnosis</a><span style="background-color: white; color: #333333; font-family: "times" , "times new roman" , serif; font-size: 10.5pt;"> were adopted: waist circumference above 88 cm, high blood sugar (fasting glucose above 100 mg/dL), high blood pressure (above 130/85 mmHg), and abnormal le</span>vels<span style="background-color: white; color: #333333; font-family: "times" , "times new roman" , serif; font-size: 10.5pt;"> of triglycerides (above 150 mg/dL) and cholesterol (HDL below 50 mg/dL). if three or more of these criteria were established then the patient was considered as diagnosed with </span>MetS<span style="background-color: white; color: #333333; font-family: "times" , "times new roman" , serif; font-size: 10.5pt;">.</span></div>
<span style="font-family: "times" , "times new roman" , serif;"><o:p></o:p></span><br />
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;"><span style="font-family: "times" , "times new roman" , serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: "times" , "times new roman" , serif;"><span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;">Researches done earlier showed the existence of several mechanisms that may explain the effect of vitamin D in contribution to MetS. The best possible explanation for the association between vitamin D deficiency and its risk factors in women is that vitamin D influences insulin secretion and sensitivity, which play a major role in MetS.</span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;"><span style="font-family: "times" , "times new roman" , serif;"><br /></span></span></div>
<div style="text-align: left;">
</div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;"><span style="font-family: "times" , "times new roman" , serif;">Insulin-secreting pancreatic beta cells expressed the <a href="https://heart.cardiologymeeting.com/">vitamin D</a> receptor and in peripheral target tissues such as skeletal muscle and adipose tissue. Vitamin D deficiency can compromise the capacity of beta cells to convert proinsulin to insulin<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;"><span style="font-family: "times" , "times new roman" , serif;"><br /></span></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgXzf7P65gqzPXCzdGFTgbl_pHu0Y3KDOTrjKfGy4a4i1Q4DhHGpdN3ZxCj85pNn28ZGjEGo4622E7rGCctpEU5ZImEkkWCcCkywFs2SIslPq0YRiSTJ2TfQZAgkqKXzrGsw-0weKSiDveS/s1600/blog+13_07_18.png" imageanchor="1" style="font-family: Times, "Times New Roman", serif; margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="315" data-original-width="600" height="210" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgXzf7P65gqzPXCzdGFTgbl_pHu0Y3KDOTrjKfGy4a4i1Q4DhHGpdN3ZxCj85pNn28ZGjEGo4622E7rGCctpEU5ZImEkkWCcCkywFs2SIslPq0YRiSTJ2TfQZAgkqKXzrGsw-0weKSiDveS/s400/blog+13_07_18.png" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
For more visit: https://heart.cardiologymeeting.com/</div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="MsoNormal" style="text-align: left;">
<span style="background: white; color: #333333; font-size: 10.5pt; line-height: 115%;"></span></div>
<div style="height: 0px; text-align: left;">
<br /></div>
</div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-1295482957455519992018-06-29T21:09:00.001-07:002018-06-29T21:09:19.869-07:00“Therepi” Can Be Used To Restore Cardiac Function.<div dir="ltr" style="text-align: left;" trbidi="on">
<span style="font-family: "times new roman", serif; font-size: 12pt; text-align: justify;">Researchers are hoping to stop the progression from heart attack to heart failure with a small device called '</span>Therepi<span style="font-family: "times new roman", serif; font-size: 12pt; text-align: justify;">.' The device contains a reservoir that attaches directly to the damaged heart tissue. There exists a refill line that connects under the patient's skin reservoir and port, where therapies can be easily injected either by the patient or a healthcare professional.</span><br />
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">After suffering from the heart attack this device could be to deliver therapy to prevent a patient from further getting heart failure.<o:p></o:p></span></div>
<div class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; margin-left: 0cm; margin-right: 0cm; margin-top: 18.75pt; mso-outline-level: 1; text-align: justify;">
<span style="color: #2b2b2b; font-family: "times new roman" , "serif"; font-size: 12.0pt; letter-spacing: -0.25pt;">'Therepi' device attaches </span><span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">directly to the damaged heart, allowing the delivery of collective therapy doses to be delivered from a port under a patient's skin to improve cardiac function</span><span style="color: #2b2b2b; font-family: "times new roman" , "serif"; font-size: 12.0pt; letter-spacing: -0.25pt;">. </span><span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">After the heart attack, a patient faces a cascade of events leading to heart failure. Scar tissues are developed due to damage caused to the area in the heart where there is blocked blood vessel. Due to scarring, the heart will remodel itself and try to cancel its effect. This process often ends in ventricular or valve failure.</span><span style="color: #2b2b2b; font-family: "times new roman" , "serif"; font-size: 12.0pt; letter-spacing: -0.25pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">Two of the most common systems lately used for delivering of drugs to prevent heart failure is inefficient and invasive. One method follows systemically drugs are delivery where drugs are delivered rather than being administered directly to the site of the damaged area. There has to control over the volume of drugs administered has and it should be limited amount to avoid toxic side effects. Often only a small amount of therapies reaches the damaged heart tissue.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">The other method involves an invasive procedure wherein therapies t is directly injected into the heart muscle. This turns out to be invasive surgeries as multiple doses are required.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">Therepi addresses the problems with current drug delivery methods by using localized, non-invasive therapies as many times as needed. The reservoir of devices can be implanted over the heart in just one surgical procedure.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">The reservoir itself is designed in a way that it has amazing potential to holds drug for drug delivery. It is constructed out of a gelatine-based polymer; its shape is a half-spherical shape with a flat bottom attached to the diseased tissue. The flat bottom comprises of a semi-permeable membrane that can be adjusted to allow the amount of drugs materials that has to pass directly into the heart tissue.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">The material used to construct the reservoir was very crucial. It should have the property similar to a sponge so it could retain the therapy in place. Which was very difficult to accomplish as the heart is constantly squeezing and moving.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">The reservoir provides a unique opportunity for administration of stem cell therapies and acts as a cell factory. The cells stay within the reservoir where they produce paracrine factors that promote healing in the damaged heart tissue, rather passing through the membrane into the heart.<o:p></o:p></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<br /></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; text-align: justify;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">In a study conducted with a rat model, the device had shown to be very effective in improvising heart function after a cardiac attack. For a four-week period, researchers administered multiple doses of cells to damaged heart areas and then analyzed the hemodynamic variance in the tissue using a pressure-volume catheter and echocardiography to compare changes for a considerate period of time. Many the groups of the model had recovered some heart function and also it was seen that the hearts that received multiple dosages of cells via therapy had more cardiac function than those who received only a single injection or no treatment at all.<o:p></o:p></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh9rVmKXWjZKSH322555rXlawlsneJxHB5aLNdatghF_ZZezEWPBAOpmHcuwKTwxvMCZxeXeqgUYZ6q2jVe7pveC6r3PeKEEU0mPtgZDK-XZFMTbFcidoHb-WetefDpziBOZ7SpTBNoNsFd/s1600/heart+2019.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="360" data-original-width="480" height="300" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh9rVmKXWjZKSH322555rXlawlsneJxHB5aLNdatghF_ZZezEWPBAOpmHcuwKTwxvMCZxeXeqgUYZ6q2jVe7pveC6r3PeKEEU0mPtgZDK-XZFMTbFcidoHb-WetefDpziBOZ7SpTBNoNsFd/s400/heart+2019.png" width="400" /></a></div>
<br /></div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-48189338709933804652018-06-21T22:31:00.001-07:002018-06-21T23:49:43.889-07:00New Research finding which can help repair damaged heart using self-healing heart cells <div dir="ltr" style="text-align: left;" trbidi="on">
<span style="font-family: Times, Times New Roman, serif;"><span class="words" style="text-align: justify;"><span style="line-height: 115%;">Researchers </span></span><span style="line-height: 115%; text-align: justify;">have </span><span class="words" style="text-align: justify;"><span data-synonyms="discovered;found" style="box-sizing: border-box; cursor: pointer;" title="">found</span></span><span style="float: none; text-align: justify;"> a potential </span><span data-synonyms="means;implies" style="box-sizing: border-box; cursor: pointer; text-align: justify;" title="">way to trigger </span><span class="words" style="text-align: justify;"><span data-synonyms="damaged;harmed" style="box-sizing: border-box; cursor: pointer;" title="">harmed</span></span><span style="float: none; text-align: justify;"> <a href="https://heart.cardiologymeeting.com/events-list/heart-regeneration">heart
cells</a> to self-heal. This has dynamic impact in treatment of heart ailments.
<span class="words">Analysts</span></span><span style="float: none; text-align: justify;"> have </span><span class="words" style="text-align: justify;"><span data-synonyms="identified;recognized;distinguished" style="box-sizing: border-box; cursor: pointer;">recognized</span></span><span style="float: none; text-align: justify;"> a long non-coding ribonucleic </span><span class="words" style="text-align: justify;"><span data-synonyms="acid;corrosive" style="box-sizing: border-box; cursor: pointer;" title="">corrosive</span></span><span style="float: none; text-align: justify;"> (ncRNA) that </span><span class="words" style="text-align: justify;"><span data-synonyms="regulates;controls;directs" style="box-sizing: border-box; cursor: pointer;">controls</span></span><span style="float: none; text-align: justify;"> </span><span class="words" style="text-align: justify;"><span data-synonyms="genes;qualities" style="box-sizing: border-box; cursor: pointer;">qualities</span></span><span style="float: none; text-align: justify;"> controlling the </span><span class="words" style="text-align: justify;"><span data-synonyms="ability;capacity" style="box-sizing: border-box; cursor: pointer;" title="">capacity</span></span><span style="float: none; text-align: justify;"> of heart cells to </span><span class="words" style="text-align: justify;"><span data-synonyms="undergo;experience" style="box-sizing: border-box; cursor: pointer;">experience</span></span><span style="float: none; text-align: justify;"> repair or </span><span class="words" style="text-align: justify;"><span data-synonyms="regeneration;recovery" style="box-sizing: border-box; cursor: pointer;">recovery</span></span><span style="float: none; text-align: justify;">. This novel RNA, which </span><span class="words" style="text-align: justify;"><span data-synonyms="researchers;analysts" style="box-sizing: border-box; cursor: pointer;">analysts</span></span><span style="float: none; text-align: justify;"> have named
"Singheart", may be </span><span class="words" style="text-align: justify;"><span data-synonyms="targeted;focused on" style="box-sizing: border-box; cursor: pointer;" title="">focused on</span></span><span style="float: none; text-align: justify;"> for treating <a href="https://heart.cardiologymeeting.com/events-list/heart-disease-and-failure">heart failure </a><span class="words">within the</span></span><span style="float: none; text-align: justify;"> future expectance. The </span><span class="words" style="text-align: justify;"><span data-synonyms="discovery;disclosure;revelation" style="box-sizing: border-box; cursor: pointer;">revelation</span></span><span style="float: none; text-align: justify;"> was made </span><span class="words" style="text-align: justify;"><span data-synonyms="jointly;mutually;together" style="box-sizing: border-box; cursor: pointer;">together</span></span><span style="float: none; text-align: justify;"> by A*STAR's Genome </span><span class="words" style="text-align: justify;"><span data-synonyms="Institute;Established;Founded;Organized" style="box-sizing: border-box; cursor: pointer;" title="">Founded</span></span><span style="float: none; text-align: justify;"> of Singapore (GIS) and the National </span><span class="words" style="text-align: justify;"><span data-synonyms="University;College" style="box-sizing: border-box; cursor: pointer;">College</span></span><span style="float: none; text-align: justify;"> </span><span class="words" style="text-align: justify;"><span data-synonyms="Health;Wellbeing" style="box-sizing: border-box; cursor: pointer;">Wellbeing</span></span><span style="float: none; text-align: justify;"> </span><span class="words" style="text-align: justify;"><span data-synonyms="System;Framework" style="box-sizing: border-box; cursor: pointer;" title="">Framework</span></span><span style="float: none; text-align: justify;"> (NUHS), and is </span><span class="words" style="text-align: justify;"><span data-synonyms="now;presently" style="box-sizing: border-box; cursor: pointer;">presently</span></span><span style="float: none; text-align: justify;"> </span><span class="words" style="text-align: justify;"><span data-synonyms="published;distributed" style="box-sizing: border-box; cursor: pointer;">distributed</span></span><span style="float: none; text-align: justify;"> in Nature Communications.</span></span><br />
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="-webkit-text-stroke-width: 0px; float: none; font-family: Times, Times New Roman, serif; font-variant-caps: normal; font-variant-ligatures: normal; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; widows: 2; word-spacing: 0px;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif; line-height: 115%;">Unlike newts and
salamanders, humans do not have ability to spontaneously regenerate damaged
cells and tissues of organs such as the <a href="https://heart.cardiologymeeting.com/">heart</a>. However, recent research
has found that mammals can have ability to regenerate the heart for a very
short period of time, when they are around in the first week of their life. But
this doesn’t last for long and hence the ability to regenerate is lost quickly.
MacLellan said “But if we had it once, maybe it is possible to regain that
ability”.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><span style="background: white; color: #333333; line-height: 115%;">The team of researchers and scientist discovered that a
unique subpopulation of damaged heart cells activates gene programmes related
to heart cell division, disclosing the <a href="https://heart.cardiologymeeting.com/events-list/heart-disease-diagnosis-and-testing">gene
expression</a> heterogeneity of damaged heart cells for the very first time. Additionally,
they also came across the "brakes" that prevents the heart cells from
further dividing and blocking its self-healing capability. Targeting these
"brakes" could potentially trigger the <a href="https://heart.cardiologymeeting.com/events-list/heart-regeneration">regeneration</a>
of damaged heart cells.</span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="background: white; color: #333333; font-family: Times, Times New Roman, serif; line-height: 115%;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><span style="color: #333333; line-height: 115%;">This new research</span><span style="line-height: 115%;">
of repairing damaged heart using self-healing heart cells <span style="color: #333333;">is a significant step in unlocking the heart's full potential
in regeneration, and may thereby help to discover more effective treatment for <a href="https://heart.cardiologymeeting.com/events-list/heart-disease-and-failure">heart
diseases</a>. Heart disease is the top disease burden throughout the world and
strong funding remains urgently needed to enable similar </span><span style="background: white; color: #222222;">pioneering</span></span><span style="color: #333333;"> discoveries as said by Prof Mark Richards, Director of
CVRI.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Times, Times New Roman, serif;"><span style="color: #0000ee; font-family: "times new roman" , serif;"><u><br /></u></span><span style="color: #333333; line-height: 115%;"><a href="https://heart.cardiologymeeting.com/"></a></span></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhLvyBnEgByDqoQixlYckWGTLLc6oFUcGtklLeGrPxYupoomE8J6OCoAAU1DewxC8qwCw12kHM8COEY3IqqB7X5qBakPYZdyipFp2L4UH9vPoiiIm5SE0PCB2YE4Jb0ut_OOWYiph181cw3/s1600/heart+regenerationm.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: Times, Times New Roman, serif;"><img border="0" data-original-height="360" data-original-width="480" height="300" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhLvyBnEgByDqoQixlYckWGTLLc6oFUcGtklLeGrPxYupoomE8J6OCoAAU1DewxC8qwCw12kHM8COEY3IqqB7X5qBakPYZdyipFp2L4UH9vPoiiIm5SE0PCB2YE4Jb0ut_OOWYiph181cw3/s400/heart+regenerationm.png" width="400" /></span></a></div>
<span style="font-family: Times, Times New Roman, serif;"><span style="line-height: 115%;"><o:p></o:p></span><br /></span>
<span style="font-family: Times, Times New Roman, serif;"><span style="color: #333333; text-align: justify;">For more details: </span><a href="https://heart.cardiologymeeting.com/" style="text-align: justify;">//heart.cardiologymeeting.com/</a></span><br />
<div align="center" style="background: white; margin-bottom: 11.25pt; margin-left: 0cm; margin-right: 0cm; margin-top: 3.75pt; text-align: center;">
<br /></div>
<div class="MsoNormal" style="tab-stops: 333.0pt;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt; line-height: 115%;"><span style="mso-tab-count: 1;"> </span><o:p></o:p></span></div>
<br /></div>
Anawilsonhttp://www.blogger.com/profile/07926537772074215601noreply@blogger.com0tag:blogger.com,1999:blog-4836903077060809822.post-46824432519935520102018-06-04T23:31:00.002-07:002018-06-07T20:21:52.186-07:00HEART 2019<div dir="ltr" style="text-align: left;" trbidi="on">
<h2 class="heading-highlights" style="background: rgb(56, 138, 187); border-radius: 4px 4px 0px 0px; box-shadow: rgba(0, 0, 0, 0.2) 1px 1px 1px; box-sizing: border-box; color: white; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 22px; font-weight: 500; line-height: 1.1; margin: 0px; padding: 5px 45px; position: relative;">
About Conference</h2>
<br /><a href="https://heart.cardiologymeeting.com/events-list/current-research-in-cardiology">"Middle East Heart Congress "</a> which will be held amid March 18-20, 2019 Dubai, UAE. Heart 2019 gathering aims to unite the most dedicated minds in the business, driving Physicians, Medical Practitioners, Surgeons, Nurses and scholastics everywhere throughout the nations to share thoughts and feature their accomplishments. Offering chance to find out about the unpredictability of the heart maladies, talk about interventional systems, take a glance through new and progressed cardiovascular practices and their proficiency and adequacy in the treatment of different cases, and comprehend neighborhood substances and viable imperatives in enhancing understanding consideration. Notwithstanding giving analysts a place to exhibit their discoveries and information, it will likewise help increment open commitment with science and group.<br /><br />Occasions identified with cardiology have a wide extension scope throughout the world. These major logical occasions come up completely examined to proffer the best prospect for the academicians regarding joint efforts to embrace the International workshops to introduce their examination, and exchange experts, showing their items and administrations and B2B networking. The logical meetings incorporate oral and publication introductions, courses, and workshops from the experts working in the field of cardiology. We are experienced coordinators of gatherings, displays, and workshops. Our meetings offer world-class content, extraordinary delegate understanding and remarkable systems administration openings in directing cardiology understudies, cardiologists, researchers, inquire about researchers, therapeutic specialists, driving restorative enterprises to champion proficient and social association with sister associations and effectively agree inside the examination and safe use of the solution with respect and morals.<br /><br /><br /><div>
<h2 class="heading-highlights" style="background: rgb(56, 138, 187); border-radius: 4px 4px 0px 0px; box-shadow: rgba(0, 0, 0, 0.2) 1px 1px 1px; box-sizing: border-box; color: white; font-family: "helvetica neue", helvetica, arial, sans-serif; font-size: 22px; font-weight: 500; line-height: 1.1; margin: 0px; padding: 5px 45px; position: relative;">
Conference Highlights</h2>
</div>
<br /><ul style="text-align: left;">
<li><a href="https://heart.cardiologymeeting.com/events-list/clinical-cardiology">Clinical Cardiology</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/current-research-in-cardiology">Current Research in Cardiology</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/cardiac-and-cardiovascular-research">Cardiac and Cardiovascular Research</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/cardiologists">Cardiologists</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/pediatric-cardiology">Pediatric Cardiology</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/diabetes-obesity-and-stroke">Diabetes, Obesity and Stroke</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/cardiac-oncology">Cardiac- Oncology</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/cardiovascular-disease-and-nutrition">Cardiovascular Disease and Nutrition</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/heart-disease-and-failure">Heart Disease and Failure</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/women-and-heart-disease">Women and Heart Disease</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/heart-disease-diagnosis-and-testing">Heart Disease: Diagnosis and Testing</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/cardiac-surgery">Cardiac Surgery</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/heart-devices">Heart Devices</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/heart-regeneration">Heart Regeneration</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/cardiovascular-pharmacology">Cardiovascular Pharmacology</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/cardiac-nursing">Cardiac Nursing</a></li>
<li><a href="https://heart.cardiologymeeting.com/events-list/case-reports-on-cardiology">Case Reports on Cardiology</a></li>
</ul>
<div>
<br />
<h2 class="heading-highlights" style="background: rgb(56, 138, 187); border-radius: 4px 4px 0px 0px; box-shadow: rgba(0, 0, 0, 0.2) 1px 1px 1px; box-sizing: border-box; color: #222222; font-family: "helvetica neue", helvetica, arial, sans-serif; font-size: 22px; font-weight: 500; line-height: 1.1; margin: 0px; padding: 5px 45px; position: relative;">
<span style="color: #f3f3f3; font-family: "oxygen" , sans-serif;">Special Issues</span></h2>
<div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<o:p></o:p></div>
<div style="background-color: white; color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;">
<div class="MsoNormal">
<o:p></o:p></div>
<div>
<div style="text-align: justify;">
<br /></div>
<div class="MsoNormal">
<span style="font-family: "times new roman" , serif; font-size: 12pt; line-height: 18.4px;"></span></div>
<div style="text-align: justify;">
<ul style="line-height: 1.4; margin: 0.5em 0px; padding: 0px 2.5em;">
<li style="margin: 0px 0px 0.25em; padding: 0px;">All accepted abstracts will be published in respective Supported International Journals.</li>
<li style="margin: 0px 0px 0.25em; padding: 0px;">Abstracts will be provided with Digital Object Identifier by CrossRef</li>
</ul>
<div>
<br /></div>
</div>
</div>
</div>
<div class="MsoNormal" style="background-color: white; text-align: left;">
<o:p style="color: #222222; font-family: Arial, Tahoma, Helvetica, FreeSans, sans-serif; font-size: 13.2px;"><span style="font-family: "arial" , "tahoma" , "helvetica" , "freesans" , sans-serif; text-align: justify;">See more at </span></o:p><span style="background-color: transparent; font-size: 13.2px;"><span style="color: #ff9900; font-family: "arial" , "tahoma" , "helvetica" , "freesans" , sans-serif;"><a href="https://heart.cardiologymeeting.com/">https://heart.cardiologymeeting.com/</a></span></span></div>
</div>
<div class="MsoNormal">
<br /></div>
</div>
</div>
Asia Pacific Conferencehttp://www.blogger.com/profile/10138955357050690328noreply@blogger.com0